Clinical trial
Extension Study to VEG105192 to Assess Pazopanib in Patients With…
NCT00387764 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00387764 |
|---|---|
| Title | Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer |
| Official title | An Open-label Extension Study to Assess the Safety and Efficacy of Pazopanib in Subjects With Renal Cell Carcinoma Previously Enrolled on Protocol VEG105192 |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell |
| Intervention type | Drug |
| Interventions | pazopanib |
| Enrollment | 80 |
| Start date | Sep 1, 2006 |
| Primary completion | Dec 1, 2009 |
| Completion | Oct 1, 2012 |
| First posted | Oct 13, 2006 |
| Last update posted | Jan 14, 2014 |
| Countries | Argentina, Australia, Austria, Brazil, Chile, China, Czechia, Estonia, Italy, Latvia, Lithuania, New Zealand and 8 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: